COPENHAGEN, Denmark: Novo Nordisk’s flagship weight-loss drug, Wegovy, has been approved for use in China, the Danish pharmaceutical giant announced. The approval covers individuals who are overweight or obese with at least one weight-related comorbidity. Although the launch date in China remains unspecified, Novo Nordisk’s sales in the country rose by 11 percent last year. Wegovy, based on the semaglutide molecule, is expected to revolutionize obesity treatment. The drug’s patent in China expires in 2026. In the United States, Wegovy has also been approved to treat heart disease in overweight or obese adults.
Where Integrity is Everything
